Gabriela Galicia-Vázquez

Gabriela Galicia-Vázquez

Auto-generated profile, based on publicly available information

Gabriela Galicia-Vázquez

Department of Biochemistry, McGill University, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Immunity
Verified
Journal Article
Closed access
JBJulianna Blagih
Julianna Blagih
FCFrançois Coulombe
François Coulombe
EVEmma Elizabeth Vincent
Emma Elizabeth Vincent
FDFanny Dupuy
Fanny Dupuy
GGGabriela Galicia-Vázquez
Gabriela Galicia-Vázquez
RJRussell G. Jones
Russell G. Jones

29 April 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RCRegina Cencic
Regina Cencic
MCMarilyn Carrier
Marilyn Carrier
GGGabriela Galicia-Vázquez
Gabriela Galicia-Vázquez
MBMarie-Eve Bordeleau
Marie-Eve Bordeleau
RSRami Sukarieh
Rami Sukarieh
JPJerry Pelletier
Jerry Pelletier
Flavaglines are a family of natural products from the genus Aglaia that exhibit anti-cancer activity in vitro and in vivo and inhibit translation initiation. They have been shown to modulate the activity of eIF4A, the DEAD-box RNA helicase subunit of the eukaryotic initiation factor (eIF) 4F complex, a complex that stimulates ribosome recruitment during translation initiation. One flavagline, silvestrol, is capable of modulating chemosensitivity in a mechanism-based mouse model. Among a number of flavagline family members tested herein, we find that silvestrol is the more potent translation inhibitor among these. We find that silvestrol impairs the ribosome recruitment step of translation initiation by affecting the composition of the eukaryotic initiation factor (eIF) 4F complex. We show that silvestrol exhibits significant anticancer activity in human breast and prostate cancer xenograft models, and that this is associated with increased apoptosis, decreased proliferation, and inhibition of angiogenesis. We demonstrate that targeting translation by silvestrol results in preferential inhibition of weakly initiating mRNAs. Our results indicate that silvestrol is a potent anti-cancer compound in vivo that exerts its activity by affecting survival pathways as well as angiogenesis. We propose that silvestrol mediates its effects by preferentially inhibiting translation of malignancy-related mRNAs. Silvestrol appears to be well tolerated in animals.

7 May 2013 in ACS Chemical Biology
Verified
Journal Article
Closed access
HSHeather Sadlish
Heather Sadlish
GGGabriela Galicia-Vazquez
Gabriela Galicia-Vazquez
CPC. Gregory Paris
C. Gregory Paris
TAThomas Aust
Thomas Aust
BBBhupinder Bhullar
Bhupinder Bhullar
NMN. Rao Movva
N. Rao Movva

15 May 2012 in RNA
Verified
Journal Article
Open access
PDF file
GGGabriela Galicia-Vázquez
Gabriela Galicia-Vázquez
RCRegina Cencic
Regina Cencic
FRFrancis Robert
Francis Robert
AAAouod Quang Agenor
Aouod Quang Agenor
JPJerry Pelletier
Jerry Pelletier
The recruitment of ribosomes to eukaryotic cellular mRNAs requires the activity of two prototypic RNA helicases, eukaryotic initiation factor (eIF) 4AI and eIF4AII. The eIF4A isoforms are highly conserved, are thought to be functionally interchangeable, and are directed to the 5′ m7GpppN cap structure of mRNAs during translation initiation by virtue of their assembly into eIF4F, a heterotrimeric complex that also harbors the eIF4E cap binding protein and eIF4G scaffolding unit. During the course of RNA interference experiments aimed at investigating the respective roles of eIF4AI and eIF4AII in translation, we uncovered a cellular response pathway whereby suppression of eIF4AI increases transcription of the eIF4AII gene, leading to elevated eIF4AII mRNA and protein levels. Inhibition of eIF4AI suppresses protein synthesis, and although eIF4AII protein levels increase above and beyond what should be sufficient to compensate for the decrease in eIF4AI levels, there is no corresponding rescue of translation or of the block on cellular proliferation that occurs upon eIF4AI suppression. These results were phenocopied using the small molecule eIF4A inhibitor hippuristanol. Taken together, our results indicate that eIF4AI and eIF4AII expression appear linked and that the two protein isoforms exhibit functional differences.

1 June 2016 in Cell Reports
Verified
Journal Article
Open access
JCJennifer Chu
Jennifer Chu
GGGabriela Galicia-Vázquez
Gabriela Galicia-Vázquez
RCRegina Cencic
Regina Cencic
JMJohn R. Mills
John R. Mills
AKAlexandra Katigbak
Alexandra Katigbak
JPJerry Pelletier
Jerry Pelletier
Targeting translation initiation is an emerging anti-neoplastic strategy that capitalizes on de-regulated upstream MAPK and PI3K-mTOR signaling pathways in cancers. A key regulator of translation that controls ribosome recruitment flux is eukaryotic initiation factor (eIF) 4F, a hetero-trimeric complex composed of the cap binding protein eIF4E, the scaffolding protein eIF4G, and the RNA helicase eIF4A. Small molecule inhibitors targeting eIF4F display promising anti-neoplastic activity in preclinical settings. Among these are some rocaglate family members that are well tolerated in vivo, deplete eIF4F of its eIF4A helicase subunit, have shown activity as single agents in several xenograft models, and can reverse acquired resistance to MAPK and PI3K-mTOR targeted therapies. Herein, we highlight the power of using genetic complementation approaches and CRISPR/Cas9-mediated editing for drug-target validation ex vivo and in vivo, linking the anti-tumor properties of rocaglates to eIF4A inhibition.

19 July 2013 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
RCR Cencic
R Cencic
FRF Robert
F Robert
GGG Galicia-Vázquez
G Galicia-Vázquez
AMA Malina
A Malina
KRK Ravindar
K Ravindar
JPJerry Pelletier
Jerry Pelletier
Translation is regulated predominantly at the initiation phase by several signal transduction pathways that are often usurped in human cancers, including the PI3K/Akt/mTOR axis. mTOR exerts unique administration over translation by regulating assembly of eukaryotic initiation factor (eIF) 4F, a heterotrimeric complex responsible for recruiting 40S ribosomes (and associated factors) to mRNA 5′ cap structures. Hence, there is much interest in targeted therapies that block eIF4F activity to assess the consequences on tumor cell growth and chemotherapy response. We report here that hippuristanol (Hipp), a translation initiation inhibitor that selectively inhibits the eIF4F RNA helicase subunit, eIF4A, resensitizes Eμ-Myc lymphomas to DNA damaging agents, including those that overexpress eIF4E—a modifier of rapamycin responsiveness. As Mcl-1 levels are significantly affected by Hipp, combining its use with the Bcl-2 family inhibitor, ABT-737, leads to a potent synergistic response in triggering cell death in mouse and human lymphoma and leukemia cells. Suppression of eIF4AI using RNA interference also synergized with ABT-737 in murine lymphomas, highlighting eIF4AI as a therapeutic target for modulating tumor cell response to chemotherapy.